About the Trial In a post-Roe v. Wade world, a medication that 63% of women use to undergo an abortion is under consideration by the Supreme Court. Mifepristone was approved as a two-drug regimen for use up to seven weeks of pregnancy and initially required in-person clinical visits, but changes by the FDA were made in 2016 and 2021 to expand accessibility via telehealth and the length of its administration. FDA v. Alliance for Hippocratic Medicine seeks to address whether the FDA's approval process was thorough and whether the drug should continue to be available. Those in favor of restrictions argue that the…